Get Updates

Research & Clinical Trials

FORCE has a strong commitment to promoting research to benefit our community. We advocate for more research funding, educate people about available studies, and report findings back to our community.

| More

Featured Research

For a listing of other research studies recruiting patients please visit our Active Studies page.

OlympiAD
OlympiAD

A phase III study comparing the PARP inhibitor olaparib to standard chemotherapy in patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation

EMBRACA
EMBRACA

BioMarin is enrolling EMBRACA, a Phase 3 study of talazoparib, a PARP inhibitor, in patients with locally advanced and/or metastatic BRCA+ breast cancer: www.embracastudy.com

Survey on risk reduction options for BRCA1 or BRCA2 positive women
Survey on risk reduction options for BRCA1 or BRCA2 positive women

If you are a woman with a BRCA mutation, please complete this 45-minute online survey to help researchers understand how you think about treatments to reduce your risk of developing breast and ovarian cancer.

BRAVO
BRAVO

A study investigating the PARP inhibitor niraparib for women with previously treated HER2 negative, BRCA positive breast cancer.

ABOUT Patient Powered Research Network
ABOUT Patient Powered Research Network

The ABOUT Network is the first-ever patient-powered research registry created and governed by and for people affected by HBOC.

NOVA Study
NOVA Study

A maintenance study investigating the PARP inhibitor niraparib for women with ovarian cancer who have high grade serous histology or known BRCA mutation and are platinum sensitive.

BROCADE Study
BROCADE Study

A treatment study investigating the PARP inhibitor veliparib for people with advanced breast cancer who have a BRCA 1 or BRCA 2 mutation.

RUCAPANC
RUCAPANC

The RUCAPANC trial is an open-label, multi-center, Phase 2 study of rucaparib in patients with advanced pancreatic cancer and a known BRCA1 or BRCA2 mutation.

Basser Research Center for BRCA
Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center.

ARIEL 3
ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer.

FORCE Research Surveys
FORCE Research Surveys

FORCE conducts surveys to better understand and address the needs of our community. By participating, you can help advance hereditary breast and ovarian cancer research.

Salpingectomy Research Registry
Salpingectomy Research Registry

Study for women who have had their fallopian tubes surgically removed and kept one or both of your ovaries to reduce their ovarian cancer risk.

INFORM Study
INFORM Study

A study for newly-diagnosed breast cancer patients who carry a BRCA1 or BRCA2 mutation.

OlympiAD OlympiAD

OlympiAD is a phase III study comparing how olaparib (a PARP inhibitor) works compared to standard chemotherapy in  patients with HER2 negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation.  Patients will be randomised 2 to 1, so patients will be twice as likely to receive olaparib than standard chemotherapy. Patients who may be eligible for the study but do not know their BRCA mutation status will be tested at no expense.

More Information

EMBRACA EMBRACA

BioMarin is enrolling EMBRACA, a Phase 3 study of talazoparib, an oral PARP inhibitor, in people with locally advanced and/or metastatic BRCA+ breast cancer. Two-thirds of study participants will be randomly selected to receive talazoparib and one-third will receive single-agent chemotherapy. All study-related medication and care will be provided, including a genetic test for BRCA mutation for those who qualify and have not yet been tested. 

More Information

Survey on risk reduction options for BRCA1 or BRCA2 positive women Survey on risk reduction options for BRCA1 or BRCA2 positive women

RTI International, a non-profit research organization, is recruiting women to participate in an opinion survey. The survey will ask you questions about your experience living with a BRCA1 or BRCA2 mutation, and your opinions about current and potential treatments that can reduce the risk of developing breast or ovarian cancers.

To help with this research, please use the link below to take this survey. The survey is open to women who have tested positive for a mutation in BRCA1 or BRCA2 genes, age 25-55, with no previous diagnosis of breast or ovarian cancer.

More Information

BRAVO BRAVO

BRAVO is a trial for men and women who have HER2 negative, BRCA mutation positive (hereditary) breast cancer that has progressed after previous treatment. The study will look at how well niraparib (a PARP inhibitor) works compared with standard chemotherapy. Patients will be randomized 2 to 1 so that two patients will take niraparib and one will take their doctor’s choice of chemotherapy. Collaborators for this international trial include the Breast International Group (BIG) and the European Organisation for Research and Treatment of Cancer (EORTC).

Visit clinicaltrials.gov at: http://clinicaltrials.gov/ct2/show/NCT01905592 or http://www.tesarobio.com


 

More Information

ABOUT Patient Powered Research Network ABOUT Patient Powered Research Network

ABOUT is the first ever research registry created and governed byand for people affected by HBOC. The ABOUT Network is a "patient-powered" research registry and one of only 29 networks chosen for participation in the National Patient Centered Outcomes Research Network (known as PCORnet). Our goal is to enroll as many Americans with HBOC as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

More Information

NOVA Study NOVA Study

NOVA is a maintenance trial for women aged 18 and older with ovarian cancer to find out if niraparib (a PARP inhibitor) can help delay worsening of ovarian cancer among patients who had a good response to previous treatment with a platinum-type chemotherapy drug (i.e. cisplatin, carboplatin).  Niraparib will be compared to placebo and patients will be randomized so that 2 out of 3 patients will take niraparib and 1 out of 3 will take placebo.  This study is designed with the hope of preventing progression of the cancer after another treatment has caused the cancer to improve.

For more information visit:

www.tesarobio.com or http://clinicaltrials.gov/ct2/show/NCT01847274
 

More Information

BROCADE Study BROCADE Study

Men and women aged 18 years or older who have advanced (metastatic) breast cancer due to a BRCA1 or BRCA2 gene mutation are invited to see if they may qualify for the Brocade Study to determine the safety and effectiveness of the investigational PARP inhibitor medication veliparib in combination with chemotherapy.

More Information

RUCAPANC RUCAPANC

The RUCAPANC trial is an open-label, multi-center, Phase 2 study of rucaparib in up to 100 patients with advanced pancreatic cancer and a known BRCA1 or BRCA2 mutation. The study will enroll patients who have received at least 1, but no more than 2, prior chemotherapy regimen(s). Patients must be tested for the presence of a harmful BRCA gene mutation prior to being considered for the study. All patients will take rucaparib tablets twice daily until disease progression or withdrawal from study.

More Information

Basser Research Center for BRCA Basser Research Center for BRCA

Research studies open to people with a BRCA 1 or BRCA 2 mutation from Basser Research Center for BRCA within Penn’s Abramson Cancer Center. 

More Information

ARIEL 3 ARIEL 3

ARIEL3 is a Phase 3 study comparing the effects of the PARP inhibitor, rucaparib, versus a placebo in approximately 540 women with platinum-sensitive high-grade ovarian, fallopian tube, or primary peritoneal cancer. Two thirds of the participants enrolled in this study will receive rucaparib. The other third of participants will receive placebo.  If you qualify for the ARIEL3 trial, you will receive the following as part of the study: study-related physical exams, lab tests results including BRCA and the biomarker test results, the study medication (rucaparib) or placebo.
 

More Information

FORCE Research Surveys FORCE Research Surveys

FORCE conducts surveys and partners with researchers who conduct surveys to better understand and address the needs of our community. By participating in surveys for which you are eligible, you help promote and advance hereditary breast and ovarian cancer research.

More Information

Salpingectomy Research Registry Salpingectomy Research Registry

Have you had your fallopian tubes surgically removed and kept one or both of your ovaries? Did you have this surgery to reduce your ovarian cancer risk? Researchers at the University of Washington in collaboration with Facing Our Risk of Cancer Empowered (FORCE) are studying the long-term outcomes of prophylactic salpingectomy (removal of the fallopian tubes). To learn more about this research study, call 206-685-7927 or email vhy@uw.edu orkagnew@uw.edu. They cannot ensure the confidentiality of any information sent by e-mail.

More Information

INFORM Study INFORM Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited abnormality (mutation) in one of the breast cancer genes, BRCA1 or BRCA2. 

More Information

Learn about the latest breakthroughs in research and our ABOUT Network.

Featured Research

With input from our Scientific Advisory Board, FORCE critically evaluates new research articles on topics of interest to our community and makes the science understandable and accessible to our community.

Join the ABOUT Network

The goal of the ABOUT network is to enroll as many Americans with HBOC risk as possible into our research registry and to collect information and real world health care experiences that can be used along with information from medical records to improve care for people with HBOC.

FORCE:Facing Our Risk of Cancer Empowered